Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ248MR)

This product GTTS-WQ248MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Neuroblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ248MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1620MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ12634MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ10019MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ5767MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ7041MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ15879MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ821MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ9227MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.